20-12-15 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
20-12-14 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-17 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
20-11-16 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
President 59 -
Director TitleAgeSince
Director/Board Member 59 -
Director/Board Member - -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
11/16/20 Issuer sale

Director

131,728 0.3818%
11/16/20 Issuer sale

Chief Financial Officer

41,038 0.1189%
11/16/20 Issuer sale

Chairman

136,253 0.3949%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
-1.22%+5.10%+58.88%+120.29% 1,144B
-1.31%+0.95%+33.58%+69.30% 625B
-2.21%-0.04%+22.47%+95.80% 511B
+0.54%+5.69%+39.60%+65.02% 377B
+0.09%+0.94%+69.77%+43.93% 366B
+0.30%+3.44%+21.35%+50.15% 291B
-0.03%+2.55%+1.12%+24.89% 262B
-0.91%+2.22%+44.64%+59.52% 237B
-2.38%-0.40%+23.24%+97.16% 194B
Average -0.69%+6.31%+34.96%+69.56% 445.32B
Weighted average by Cap. -0.92%+6.91%+40.40%+80.99%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock